- Home
- SONN vs PTIX Comparison
SONN vs PTIX Comparison
Compare SONN & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- PTIX
- Stock Information
- Founded
- SONN N/A
- PTIX 1994
- Country
- SONN United States
- PTIX United States
- Employees
- SONN N/A
- PTIX N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- SONN Health Care
- PTIX Health Care
- Exchange
- SONN Nasdaq
- PTIX Nasdaq
- Market Cap
- SONN 3.8M
- PTIX 3.3M
- IPO Year
- SONN N/A
- PTIX 2016
- Fundamental
- Price
- SONN $1.50
- PTIX $3.59
- Analyst Decision
- SONN Strong Buy
- PTIX
- Analyst Count
- SONN 1
- PTIX 0
- Target Price
- SONN $20.00
- PTIX N/A
- AVG Volume (30 Days)
- SONN 50.9K
- PTIX 187.3K
- Earning Date
- SONN 08-13-2025
- PTIX 08-13-2025
- Dividend Yield
- SONN N/A
- PTIX N/A
- EPS Growth
- SONN N/A
- PTIX N/A
- EPS
- SONN N/A
- PTIX N/A
- Revenue
- SONN $1,000,000.00
- PTIX N/A
- Revenue This Year
- SONN $5,376.22
- PTIX N/A
- Revenue Next Year
- SONN N/A
- PTIX N/A
- P/E Ratio
- SONN N/A
- PTIX N/A
- Revenue Growth
- SONN 978.39
- PTIX N/A
- 52 Week Low
- SONN $1.08
- PTIX $2.35
- 52 Week High
- SONN $10.02
- PTIX $15.54
- Technical
- Relative Strength Index (RSI)
- SONN 70.61
- PTIX 47.73
- Support Level
- SONN $1.10
- PTIX $3.46
- Resistance Level
- SONN $1.17
- PTIX $4.19
- Average True Range (ATR)
- SONN 0.09
- PTIX 0.25
- MACD
- SONN 0.03
- PTIX 0.02
- Stochastic Oscillator
- SONN 80.37
- PTIX 32.30
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.